Genmab — Februar 2021
-
-
Det ser ud til, at 2021 bliver anderledes - nu kan vi se frem til masser af read-outs og ikke kun sidde og kigge på recepttal for dara. Det bliver lidt mere som de gode gamle dage
-
I mean, we knew the products in the pipeline, so we knew how much investment will have to go into that. So for me, higher investmenst now means bringing investments forward. So my only conclusion can be that the majority of the analysts think that Genmab is going to fast I guess?
-
It
is why I asked
@troldmanden yesterday, ‘if they would delay that 1bn for a year, so that cost would be in line with analysts expectations, would you feel better?’ Personally, I don’t understand that… -
This is one of those delightful moments, where we can put our money where out mouths are - Through the collaborations GEN has mitigated the risks of not being able to handle scale and speed in these large programs - now GEN must put up the money to make these things happen. That will hopefully be worth the investment
-
If analysts just see elevated costs - fine by me
-
Did anybody else notice the “Significant CMC investment” for both epco and GEN1046 on slide no 13 yesterday?
-
In other words - we are “buying” a factory
-
Well, there is finally need for substantial production of molecules to feed the clinical programs
-
That can’t be handled in research labs
-
That’s why i wrote “buying”
-
Absolutely - with the difference that buying a factory is not COMPLETELY insane now. Just insane
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind